1. ScholarBank@NUS

Cheng Ean Chee

rp29952

Collaboration Map View Statistics Email Alert RSS Feed

Profile

Full Name
Cheng Ean Chee
Main Affiliation
 
Faculty
 
Email
mdccce@nus.edu.sg
 

Publications

Refined By:
File Format:  Adobe PDF
Type:  Article
Department:  DUKE-NUS MEDICAL SCHOOL

Results 1-6 of 6 (Search time: 0.005 seconds).

Issue DateTitleAuthor(s)
11-Mar-2022A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignanciesHo, Jingshan ; Heong, Valerie; Yong, Wei Peng ; Soo, Ross ; Chee, Cheng Ean ; Wong, Andrea ; Sundar, Raghav; Thian, Yee Liang ; Gopinathan, Anil ; Pang, Mei Yan; Koe, Priscillia; Jeraj, Santhiay Nathan; Soe, Phyu Pyar; Soe, Mu Yar; Tang, Tiffany ; Ng, Matthew CH; Tai, David WM ; Tan, Tira JY ; Xu, Hongmei; Chang, Hua; Landesman, Yosef; Shah, Jatin ; Shacham, Sharon; Lee, Soo Chin ; Tan, Daniel SW ; Goh, Boon Cher ; Tan, David SP 
212-Apr-2023Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci; Yoon-Koo Kang; Hope E. Uronis; Keun-Wook Lee; Matthew C. H. Ng ; Peter C. Enzinger; Se Hoon Park; Philip J. Gold; Jill Lacy; Howard S. Hochster; Sang Cheul Oh; Yeul Hong Kim; Kristen A. Marrone; Ronan J. Kelly; Rosalyn A. Juergens; Jong Gwang Kim; Thierry Alcindor; Sun Jin Sym; Eun-Kee Song; Cheng Ean Chee ; Yee Chao; Sunnie Kim; Do-Youn Oh; Jennifer Yen; Justin I. Odegaard; Errin Lagow; Daner Li; Jichao Sun; Patrick Kaminker; Paul A. Moore; Minori Koshiji Rosales; Haeseong Park
32019PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoproteinThura M.; Al-Aidaroos A.Q.; Gupta A. ; Chee C.E. ; Lee S.C. ; Hui K.M. ; Li J.; Guan Y.K. ; Yong W.P. ; So J. ; Chng W.J. ; Ng C.H. ; Zhou J. ; Wang L.Z. ; Yuen J.S.P. ; Ho H.S.S. ; Yi S.M.; Chiong E. ; Choo S.P. ; Ngeow J. ; Ng M.C.H. ; Chua C. ; Yeo E.S.A. ; Tan I.B.H. ; Sng J.X.E.; Tan N.Y.Z.; Thiery J.P. ; Goh B.C. ; Zeng Q. 
42-Nov-2021PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein (vol 10, 2484, 2019)Thura, Min; Al-Aidaroos, Abdul Qader; Gupta, Abhishek ; Chee, Cheng Ean ; Lee, Soo Chin ; Hui, Kam Man ; Li, Jie; Guan, Yeoh Khay ; Yong, Wei Peng ; So, Jimmy; Chng, Wee Joo ; Ng, Chin Hin ; Zhou, Jianbiao ; Wang, Ling Zhi; Yuen, John Shyi Peng; Ho, Henry Sun Sien ; Yi, Sim Mei; Chiong, Edmund ; Choo, Su Pin ; Ngeow, Joanne; Ng, Matthew Chau Hsien ; Chua, Clarinda; Yeo, Eugene Shen Ann ; Tan, Iain Bee Huat ; Sng, Joel Xuan En; Tan, Nicholas Yan Zhi; Thiery, Jean Paul ; Goh, Boon Cher ; Zeng, Qi 
515-Aug-2022Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitorsLim, Jhin Jieh ; Hooi, Lissa ; Dan, Yock Young ; Bonney, Glenn K ; Zhou, Lei ; Chow, Pierce K-H ; Chee, Cheng Ean ; Toh, Tan Boon ; Chow, Edward K-H 
62018Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) StudyHeong V.; Syn N.L.; Lee X.W.; Sapari N.S. ; Koh X.Q.; Adam Isa Z.F. ; Sy Lim J.; Lim D. ; Pang B. ; Thian Y.L. ; Ng L.K. ; Wong A.L. ; Soo R.A. ; Yong W.P. ; Chee C.E. ; Lee S.-C., Goh B.-C. ; Soong R. ; Tan D.S.P.